Education & Training

Medical School

University of Missouri Columbia

Internship

Transitional Year

  • Mercy Hospital St. Louis-GME

Residency

Dermatology

  • University of Missouri School of Medicine GME

Fellowship

Dermatology

  • Brigham & Womens Hospital

Boards

American Board of Dermatology

Insurances

MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

Academic Information

Assistant Professor of Clinical Dermatology
Dermatological Oncology, Clinic Director

Office

1 Hospital Drive
MA 111
Columbia, MO 65212
United States

P. 573-882-8578
F. 573-884-5947

Research Profile

Jesse Hirner, MD is interested in complex medical dermatology, skin cancer prevention, dermatology education, access to dermatologic care.

Research Interests

  • Cutaneous Oncology
  • Dermatologic Oncology

Areas of Expertise

  • Cutaneous Oncology
  • Dermatologic Oncology
  • Dermatologic toxicities from anti-cancer therapies
  • Graft-versus-host disease
  • Medical Dermatology

Awards & Honors

  • 2021 – Present Multinational Association of Supportive Care in Cancer October
  • 2020 – Present Reviewer, Journal of the American Academy of Dermatology
  • 2019 – Present Diplomate, American Board of Dermatology September Massachusetts Medical Society
  • 2016 – Present Medical Dermatology Society October
  • 2016 – Present Fellow, American Academy of Dermatology

Publications

  • Becker NV, Bakshi S, Martin KL, et al including Hirner JP.
    Provider experience and satisfaction with a novel virtual team rounding program during the COVID-19 pandemic.
    Int J Qual Health Care. 2021;33(3):mzab111. doi:10.1093/intqhc/mzab111
  • Becker NV, Bakshi S, Martin KL, et al including Hirner JP.
    Virtual team rounding: A cross- specialty inpatient care staffing program during the COVID-19 pandemic.
    Acad Med. 2021. 96(12):1717-1721. doi: 10.1097/ACM.0000000000004208
  • Buy AN, Singer S, Hirner J, et al.
    Cutaneous connective tissue disease associated with immune checkpoint inhibitor therapy: a retrospective analysis.
    J Am Acad Dermatol. 2021;84(3):864-9. doi: 10.1016/j.jaad.2020.10.054
  • Bui AN, Hirner J, Singer S et al.
    De novo subacute cutaneous lupus erythematosus like eruption in the setting of PD-1 or PD-L1 inhibitor therapy: clinicopathologic correlation.
    Clin Exp Dermatol. 2021;46(2):328-37. doi: 10.1111/ced.14449
  • Talia J, Hirner JP.
    Chapter 26, BRAF inhibitors. In: Alloo A, LeBoeuf NR, editors.
    Cutaneous Toxicities to Anticancer Therapies, 1st ed. Philadelphia. Wolters Kluwer. In Press.
  • Hirner JP, Dewan A.
    Chapter 37, Programmed cell death 1 inhibitors. In: Alloo A, LeBoeuf NR, editors.
    Cutaneous Toxicities to Anticancer Therapies, 1st ed. Philadelphia. Wolters Kluwer. In Press.
  • Hirner JP.
    Chapter 6, Bites and stings. In: Walls AC editor.
    Manual of Urgent and Emergent Dermatology, 1st ed. Philadelphia. Wolters Kluwer. In Press.
  • Bui AN, Hirner J, Singer S et al.
    Cutaneous connective tissue disease associated with immune checkpoint inhibitor therapy: a retrospective analysis.
    2020 Medical Dermatology Society Meeting.